Complexity is rising in sterile injectables, driven by factors that include, but are not limited to, formulation and delivery.
Reduce complexity and save time on the way to IND authorization and first-in-human trials.
1. Despite orphan drugs being notorious for their high costs and risk factors, the market is projected to grow at 13% CAGR from 2020-20241,2. One driver of this growth is the financial incentives and benefits companies are receiving for new biologics that pertain to orphan drugs.
2. Prior to the COVID-19 Pandemic, the global mRNA therapeutics market was estimated to reach ~3B by 20262. Complex formulations that deliver mRNA or DNA using lipid nanoparticles are on the rise. These formulations behave like oil and water emulsions, which increases complexity in formulation as well as compounding.